Recce Pharmaceuticals Ltd. ( (AU:RCE) ) just unveiled an announcement.
Recce Pharmaceuticals Ltd. announced that it has received a notice of allowance from the Japan Patent Office for its anti-infectives, RECCE® 327 and RECCE® 529, with patent protection extending until 2041. This patent approval in Japan, the third largest pharmaceutical market globally, enhances Recce’s market positioning and underscores its commitment to providing innovative solutions for antibiotic resistance, a market expected to grow significantly in Japan. The patent covers various methods of administration and validates the efficacy of Recce’s products in treating a range of infections, positioning the company to deliver meaningful solutions worldwide.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. is a company focused on developing a new class of synthetic anti-infectives. Their primary products include RECCE® 327 and RECCE® 529, which are designed for the treatment of various bacterial and viral infections. The company is committed to addressing critical unmet medical needs with innovative therapies and has a global market focus.
YTD Price Performance: -10.42%
Average Trading Volume: 124,917
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$99.7M
See more data about RCE stock on TipRanks’ Stock Analysis page.